Search

748 Result(s)
Sort by

emperor-preserved-chmp-positive-opinion

emperor-preserved-chmp-positive-opinion

CHMP issues positive opinion to expand Jardiance (empagliflozin) indication based on unprecedented benefit in adult heart failure patients with preserved ejection fraction
real-world-benefit-shown-in-T2D-treatment

real-world-benefit-shown-in-T2D-treatment

Real-world evidence study shows type 2 diabetes treatment reduced risk of cardiovascular events and hospitalization for heart failure
emperor-preserved-heart-failure-full-data

emperor-preserved-heart-failure-full-data

Full results from EMPEROR-Preserved trial demonstrate significant improvement in heart failure outcomes in adults with preserved ejection fraction
empa-reg-outcome-recurrent-events

empa-reg-outcome-recurrent-events

EMPA-REG OUTCOME® analysis: Empagliflozin reduced risk of first plus recurrent cardiovascular events in adults with type 2 diabetes and CV disease
Niha Agarwalla

Niha Agarwalla

My career challenge at Boehringer Ingelheim by Niha Agarwalla. Read it now!
Finding the right inhaler for you

Finding the right inhaler for you

Living with a chronic respiratory disease can make life complicated. This discussion guide can be used to help start a conversation with a healthcare professional about inhaler choice.
H5N1: Bird flu again. What’s different now?

H5N1: Bird flu again. What’s different now?

H5N1: how is avian influenza now? The virus known for affecting wild & domestic birds has been detected in dairy cows in the US. What you need to know.
Bluetongue disease

Bluetongue disease

The bluetongue virus is a viral disease that affects ruminants' health. It doesn't affect humans, but it is a threat to animals.
Women in STEM 2022

Women in STEM 2022

Meet three of Boehringer Ingelheim's female scientists and learn why and how women are making a difference in STEM.
Fredrik Gruenenfelder

Fredrik Gruenenfelder

, Lead Risk Management Physician, talks about his career journey, from veterinarian to playing a key role in keeping patients safe.
FIBRONEER™ Phase III program initiated

FIBRONEER™ Phase III program initiated

FIBRONEER™ Phase III program initiated globally to evaluate BI 1015550, a novel investigational phosphodiesterase 4B (PDE4B) inhibitor
Digital solutions save lives

Digital solutions save lives

Michael Schmelmer explains how digital solutions shape the future of Boehringer Ingelheim and the entire healthcare industry.
FDA-approves-nintedanib-in-SSc-ILD

FDA-approves-nintedanib-in-SSc-ILD

FDA approves Ofev® as the first and only therapy in the U.S. to slow the rate of decline in pulmonary function in patients with systemic sclerosis-associated ILD